2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCross-Sectional StudiesHumansMiddle AgedNeoplasmsPeripheral Nervous System DiseasesQuality of LifeTreatment OutcomeConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptomsRetrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAlopeciaBreast NeoplasmsCyclin-Dependent Kinase 4FemaleHumansMinoxidilRetrospective StudiesTreatment OutcomeConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore grade
2019
Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy
Worthen-Chaudhari L, Lamantia M, Monfort S, Mysiw W, Chaudhari A, Lustberg M. Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy. Clinical Biomechanics 2019, 70: 257-264. PMID: 31751861, DOI: 10.1016/j.clinbiomech.2019.08.010.Peer-Reviewed Original ResearchConceptsCancer survivorsPostural controlCOP measuresMean satisfaction rateNeurotoxic cancer treatmentsBalance training programPostural control deficitsTango danceHalf of participantsPreliminary efficacySensorimotor trainingNormal rangePromising treatmentPressure measuresQuiet standingSatisfaction rateBalance deficitsCancer treatmentPilot studySurvivorsMore sessionsFeasibility criteriaTango classesControl deficitsMore studies
2017
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data
Orchard T, Andridge R, Yee L, Lustberg M. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. Journal Of The Academy Of Nutrition And Dietetics 2017, 118: 578-588.e1. PMID: 29233615, PMCID: PMC5869134, DOI: 10.1016/j.jand.2017.09.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsCancer SurvivorsCross-Sectional StudiesDietDrug-Related Side Effects and Adverse ReactionsFemaleHumansInflammationInterleukin-17Interleukin-6Middle AgedPilot ProjectsPostmenopauseQuality of LifeReceptors, Tumor Necrosis Factor, Type IITreatment OutcomeConceptsBreast cancer survivorsBody mass indexQuality of lifeLower IL-6Cancer survivorsDiet qualityIL-6Breast cancerTNFR-2QOL measuresEndocrine receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerMidwestern cancer centerModifiable lifestyle factorsSerum proinflammatory cytokinesCancer Therapy-BreastHealthy Eating IndexAromatase inhibitor treatmentCross-sectional analysisEndocrine subscaleOverall HEIPrior chemotherapyPostmenopausal womenPrimary therapyCirculating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski R, Duggan M, Stiff A, Markowitz J, Trikha P, Levine K, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Reinbolt R, Mrozek E, Byrd J, Caligiuri M, Mace T, Carson W. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy 2017, 66: 1437-1447. PMID: 28688082, PMCID: PMC5647220, DOI: 10.1007/s00262-017-2038-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlack or African AmericanBreast NeoplasmsCell CountChemotherapy, AdjuvantCyclophosphamideCytokinesDoxorubicinFemaleGranulocytesHumansMiddle AgedMonocytesMyeloid-Derived Suppressor CellsNeoadjuvant TherapyPaclitaxelPilot ProjectsTreatment OutcomeWhite PeopleConceptsMyeloid-derived suppressor cellsPathologic complete responseG-MDSC levelsNeo-adjuvant chemotherapyG-MDSCSuppressor cellsComplete responseAnti-HER2 therapyPeripheral blood levelsBreast cancer patientsAfrican American patientsBreast cancer typesCyclophosphamide therapyBlood levelsCancer patientsLast administrationAmerican patientsBreast cancerPatientsFlow cytometryCancer typesChemotherapySignificant riseConfidence intervalsCycle 1Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing
2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Mikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.Peer-Reviewed Original ResearchMeSH KeywordsActivation, MetabolicAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEnzyme InductionEsophageal NeoplasmsFatigueFemaleGene Expression Regulation, NeoplasticHematologic DiseasesHumansKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPaclitaxelPancreatic NeoplasmsProdrugsThymidine PhosphorylaseTreatment OutcomeUp-RegulationYoung AdultConceptsAdvanced solid tumorsII studyUnknown primaryDay 1Phase I/II studySolid tumorsPhase IPhase II patientsAntitumor activityObjective response ratePhase II dosePhase II studyMaximal tolerable doseSynergistic antitumor activityCessation of fundingCapecitabine 750Paclitaxel 60Disease stabilizationAcceptable tolerabilityAdvanced adenocarcinomaPartial responseCarboplatin AUCII patientsTolerable dosePatientsGene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
Oliveira-Costa J, de Carvalho A, da Silveira G, Amaya P, Wu Y, Park K, Gigliola M, Lustberg M, Buim M, Ferreira E, Kowalski L, Chalmers J, Soares F, Carraro D, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015, 6: 20902-20920. PMID: 26041877, PMCID: PMC4673238, DOI: 10.18632/oncotarget.3939.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAutoimmune DiseasesB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesCytoplasmDNA-Binding ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMouth NeoplasmsNeoplastic Cells, CirculatingOligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsTissue BanksTreatment OutcomeConceptsOral squamous cell carcinomaPD-L1Tumor sizePerineural invasionPrimary tumorAdvanced oral squamous cell carcinomaTumor cellsSquamous cell carcinoma developmentStrong cytoplasmatic expressionPD-L1 positivityDisease-specific survivalOral squamous cell carcinoma developmentPD-L1 expressionIndependent prognostic factorLymph node metastasisT cell activitySquamous cell carcinomaSub-classify patientsSpecific survivalNode metastasisPD-1Prognostic factorsPoor prognosisAutoimmune diseasesCell carcinomaNeoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response
2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Zhao M, Pan X, Layman R, Lustberg M, Mrozek E, Macrae E, Wesolowski R, Carothers S, Puhalla S, Shapiro C, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs 2014, 32: 1285-1294. PMID: 24894652, PMCID: PMC4303337, DOI: 10.1007/s10637-014-0122-5.Peer-Reviewed Original ResearchConceptsProgression-free survivalLeft ventricular ejection fractionClinical benefit rateHER2-positive MBCObjective response rateComplete responsePartial responseBreast cancerStable diseaseFree survivalGrade 3HER2-positive metastatic breast cancerResponse rateAdditional overall survival benefitsMedian progression-free survivalMetastatic breast cancer patientsPositive metastatic breast cancerVascular epithelial growth factorCommon grade 3Cycles of bevacizumabGrade 2 hypertensionMethods Eligible patientsPrior chemotherapy regimensCombination of bevacizumabHand-foot syndromeManagement options for established chemotherapy-induced peripheral neuropathy
Pachman D, Watson J, Lustberg M, Wagner-Johnston N, Chan A, Broadfield L, Cheung Y, Steer C, Storey D, Chandwani K, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi C. Management options for established chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2014, 22: 2281-2295. PMID: 24879391, DOI: 10.1007/s00520-014-2289-x.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsHumansNeoplasmsPeripheral Nervous System DiseasesTreatment OutcomeConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyTreatment of CIPNPeripheral neuropathy syndromesCancer treatment outcomesQuality of lifeClinical practice experienceCIPN treatmentNeuropathy syndromesTreatment optionsTreatment outcomesTherapeutic interventionsChemotherapeutic agentsPsychosocial functioningAvailable evidenceLimited evidenceNeuropathyPatientsTreatmentCliniciansAvailable literaturePractice experienceManagement optionsEvidenceOptionsPrevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Hershman D, Lacchetti C, Dworkin R, Lavoie Smith E, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg M, Paice J, Schneider B, Smith M, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 1941-1967. PMID: 24733808, DOI: 10.1200/jco.2013.54.0914.Peer-Reviewed Original ResearchMeSH KeywordsAdultAminesAmitriptylineAnalgesicsAnticonvulsantsAntidepressive Agents, TricyclicAntineoplastic AgentsBaclofenComorbidityCyclohexanecarboxylic AcidsDrug Therapy, CombinationDuloxetine HydrochlorideEvidence-Based MedicineGabapentinGamma-Aminobutyric AcidGelsHumansIncidenceKetamineNeoplasmsNeuralgiaPeripheral Nervous System DiseasesQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSurvivorsThiophenesTreatment OutcomeUnited StatesConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyPrimary outcomePrevention of CIPNTreatment of CIPNClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineNeuropathic pain conditionsSeverity of neuropathyClinical practice guidelinesPatient-reported outcomesAdult cancer survivorsQuality of lifeSystematic literature searchEvidence-based guidanceDifferent time pointsPain conditionsCancer survivorsTreatment optionsTricyclic antidepressantsPractice guidelinesAdult cancersNeurophysiologic changesEligibility criteriaTreatment approaches
2012
Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer
Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp M. Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging 2012, 30: 1059-1067. PMID: 22884756, PMCID: PMC3645932, DOI: 10.1016/j.mri.2012.04.026.Peer-Reviewed Original ResearchConceptsPotential imaging markerPathologic responseBreast cancerTumor heterogeneityImaging markerHER-2 negative breast cancerImaging biomarkersVolumetric biomarkersCombination neoadjuvant chemotherapyCurrent imaging studiesGood predictive biomarkerNegative breast cancerTherapeutic response assessmentNovel imaging biomarkersNeoadjuvant chemotherapyRetrospective studyPredictive biomarkersNovel biomarkersResponse assessmentHeterogeneous diseaseEarly changesImaging studiesBiomarkersCancerCellular compositionPhase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Lustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen R, Berger M, Mrozek E, Ramaswamy B, Grever M, Au J, Wientjes M, Shapiro C. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy And Pharmacology 2012, 70: 49-56. PMID: 22729159, PMCID: PMC3466596, DOI: 10.1007/s00280-012-1887-x.Peer-Reviewed Original ResearchConceptsObjective response rateMetastatic breast cancerWeekly paclitaxelAnti-tumor activityII trialBreast cancerPhase I/II trialMedian progression-free survivalGrowth factorPhase IMedian overall survivalResultsThirty-one patientsPhase II trialProgression-free survivalDose-limiting toxicityBasic fibroblast growth factorPre-specified criteriaNon-cytotoxic dosesFibroblast growth factorPrior taxaneMetastatic settingUnacceptable toxicityOverall survivalPolypeptide growth factorsSuramin concentrations
2011
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2
2010
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
Lustberg M, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero M. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal Of Thoracic Oncology 2010, 5: 713-718. PMID: 20354452, PMCID: PMC3641556, DOI: 10.1097/jto.0b013e3181d7776d.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCamptothecinCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansIrinotecanLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMitomycinNeoplasm StagingStomach NeoplasmsSurvival RateTreatment OutcomeConceptsMitomycin CDay 1Day 2Phase II Randomized StudyComplete pathologic responsePhase II evaluationGastroesophageal junction adenocarcinomaUnresectable esophagealEvaluable patientsGastroesophageal adenocarcinomaJunction adenocarcinomaPathologic responseRandomized studyArm AGastroesophageal junctionFuture trialsEsophageal cancerII evaluationSevere toxicityPatientsIrinotecanResponse ratePhase IAdenocarcinomaTopoisomerase 1
2007
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg M, Edelman M. Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Current Treatment Options In Oncology 2007, 8: 38-46. PMID: 17634834, DOI: 10.1007/s11864-007-0020-6.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyQuality of lifeLung cancerNew agentsAdvanced non-small cell lung cancerOptimal durationNon-small cell lung cancerPlatinum-based combination chemotherapyEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsBenefit of chemotherapyFirst-line chemotherapyAdditional survival benefitAdvanced stage diseaseDuration of therapyMetastatic lung cancerCell lung cancerMatrix metalloproteinase inhibitorsCytotoxic regimenPlatinum doubletsLine chemotherapySequential therapyStage diseaseCombination chemotherapyOverall survival